5:03 PM
May 08, 2014
 |  BC Extra  |  Company News

NICE now backs Xtandi regardless of Zytiga use

The U.K.'s NICE issued final Xtandi enzalutamide from Astellas Pharma Inc. (Tokyo:4503) for hormone-relapsed, metastatic prostate cancer that progressed on or after one or more docetaxel-containing regimens -- the drug's approved indication in Europe. The new draft guidance removes language included in January...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >